查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1964161

天花治療市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型、產品類型、最終用戶、地區和競爭格局分類，2021-2031年

Smallpox Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Product Type, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球天花治療市場預計將從 2025 年的 7,512 萬美元成長到 2031 年的 9,461 萬美元，複合年成長率為 3.92%。

該市場涵蓋抗病毒藥物和疫苗等醫療措施，旨在預防和治療正痘病毒感染疾病，包括天花和猴痘。該領域的成長主要受各國政府為降低生物恐怖主義風險而製定的生物防禦儲備指令以及控制通用感染疾病再次爆發的需要所驅動。這些採購舉措確保了即使在天花根除後，對已通過核准的治療方法的需求依然存在，疫苗聯盟Gavi已達成一項預購協議，將於2024年採購50萬劑疫苗以應對區域性疫情爆發，這便證明了這一點。

市場概覽
預測期 2027-2031
市場規模：2025年 7512萬美元
市場規模：2031年 9461萬美元
複合年成長率：2026-2031年 3.92%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

市場擴張的主要障礙之一是依賴時斷時續的政府契約，而非穩定的商業基本客群。對於日常使用量有限的產品而言，維護生產系統的高昂成本會為私人開發商帶來財務上的不穩定性。對公共資金週期的依賴意味著，由於政治議程的變化或預算重新分配，收入來源可能會突然減少，這反過來又會使新進業者對投資這一專業製藥領域猶豫不決。

市場促進因素

由於猴痘和正痘病毒感染疾病的反覆爆發，市場需求激增，這極大地推動了醫療物資的供應。各國紛紛將醫療物資的即時供應列為優先事項。推動這一市場成長的因素包括國際組織和各國政府採取快速反應策略，採購治療藥物和疫苗，以限制跨境病毒傳播威脅，並將應對措施從理論上的準備轉向積極主動的疾病控制。 2024年，猴痘被宣佈為國際關注的突發公共衛生事件，加速了採購管道的運轉，並迫使各國政府增加儲備以備即時。例如，2024年8月，巴伐利亞北歐公司宣布已採購175,420劑MVA-BN疫苗，以支持歐洲衛生緊急反應署（HERA）在非洲進行的危機應變工作。

同時，國家戰略生物防禦儲備的擴充為製藥研發公司提供了長期永續性的根本穩定因素。世界各國政府都認知到天花是一種嚴重的生物武器威脅，並認知到無論當前感染水平如何，都需要維持第二代疫苗和抗病毒藥物的儲備。這種以安全為導向的做法促成了多年合約的簽訂，從而保護公司免受商業性波動的影響。例如，美國衛生與公共服務部行使了一項價值1.13億美元的口服TPOXX疫苗採購選擇權，SIGA Technologies公司於2024年7月宣布了這一消息。此外，Emergent BioSolutions公司在2024年7月報告稱，該公司已獲得一項價值9990萬美元的合約修訂，將繼續向美國國家戰略儲備供應其ACAM2000疫苗，這凸顯了該行業對聯邦國防費用的依賴。

市場挑戰

對不規律的政府合約的依賴是全球天花治療市場的主要阻礙因素，造成收入環境不穩定，阻礙了私部門的穩定投資。與受持續患者需求支撐的商業製藥產業不同，天花治療市場嚴重依賴生物防禦儲備義務和不規則的採購週期。製造商必須在沒有持續銷售保障的情況下維持高成本的專業化生產能力和合規性，從而導致「繁榮與蕭條」的交替局面：一旦威脅減弱或公共衛生重點發生轉變，收入可能會驟然消失。這使得長期策略規劃變得複雜。

這種不穩定性因有條件採購而進一步加劇，因為這種採購僅限於緊急情況而非主動資金籌措。這種被動模式導致企業承擔維持產能和管理庫存的相關風險。例如，聯合國兒童基金會曾考慮在2024年進行緊急競標，以在2025年前採購多達1,200萬劑MPOX疫苗，但此次採購明確取決於已確認的需求和可用資金。這個例子表明，依賴無擔保的公共資金以及缺乏穩固的商業性消費群如何阻礙市場維持穩定的成長軌跡。

市場趨勢

製造業者と規制当局は、医薬品適応症の拡大に再び注力しています。具体的には、従来の生物防衛戦略で除外されてきた特別なリスクグループや兒童集団を対象に含めることで、歴史的な戦略上の大きな空白を埋める取り組みです。この動向には、オルソポックスウイルスに対する広範な保護を確保するため、特に兒童を対象とした規制措置や臨床試験の増加が含まれます。これにより、初期の製剤に見られた嚴重な副作用なしに、より若い被験者層で免疫を誘導する、安全性が高い第三世代ワクチンの導入へと軸足を移しつつあります。主な発展として、世界保健機関（WHO）は2024年11月、1歳以上の兒童向けLC16m8ワクチンの緊急使用許可を核准し、この脆弱な集団を保護するため、日本からコンゴ民主共和国への305万回分のワクチン寄贈を促進したことを報告しました。

生物製藥公司正在加速整合其針對疥痘和天花的開發平臺，以利用當前疫情檢驗雙適應症療法的有效性。透過利用疥痘病例的臨床數據，研發人員可以加快頻譜正痘抗病毒藥物的監管核准流程，而由於天花已被根除，此類藥物的測試原本難以進行。這種策略整合將最佳化研發支出，並使mRNA技術等新型平台能夠快速應對新出現的威脅，同時履行各國政府的長期生物防禦義務。例如，Moderna公司針對這兩種病毒的mRNA-1769候選藥物正在進行I/II期臨床試驗，相關報告發表於2024年9月的《製藥技術》雜誌。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球天花治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（抗病毒藥物、疫苗接種、支持性治療）
    • 依產品類型（疫苗、抗病毒藥物）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美天花治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲天花治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區天花治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲天花治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲天花治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球天花治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bavarian Nordic A/S
  • Chimerix, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Novartis AG
  • Johnson & Johnson
  • SIGA Technologies, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Bharat Biotech International Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18842

The Global Smallpox Treatment Market is projected to expand from USD 75.12 Million in 2025 to USD 94.61 Million by 2031, achieving a compound annual growth rate of 3.92%. This market encompasses medical countermeasures, such as antiviral therapeutics and vaccines, intended to prevent and treat orthopoxvirus infections like variola and mpox. Sector growth is chiefly upheld by government directives for biodefense stockpiling to mitigate bioterrorism risks and the need to control re-emerging zoonotic outbreaks. These procurement initiatives guarantee continued demand for approved treatments despite smallpox eradication, as evidenced by Gavi, the Vaccine Alliance, which secured an advance purchase agreement for 500,000 vaccine doses in 2024 to tackle rising regional outbreaks.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 75.12 Million
Market Size 2031USD 94.61 Million
CAGR 2026-20313.92%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

One major obstacle hindering market expansion is the reliance on intermittent government contracts rather than a steady commercial customer base. The substantial expense of preserving manufacturing readiness for products that see limited routine use introduces financial instability for private developers. Relying on public funding cycles means that changes in political agendas or budget reallocations can suddenly diminish revenue sources, thereby deterring new competitors from investing in this specialized pharmaceutical niche.

Market Driver

The market is effectively propelled by surging demand resulting from recurring mpox and orthopoxvirus outbreaks, leading nations to prioritize the immediate acquisition of medical countermeasures. This driving force involves rapid response strategies where international bodies and governments procure therapeutics and vaccines to limit transboundary viral threats, shifting from theoretical readiness to active disease management. The declaration of mpox as a public health emergency in 2024 hastened these procurement channels, forcing authorities to increase inventories for immediate use; for instance, Bavarian Nordic announced in August 2024 that the European Health Emergency Preparedness and Response Authority (HERA) purchased 175,420 doses of the MVA-BN vaccine to aid the response to the crisis in Africa.

Concurrently, the growth of national strategic biodefense stockpiles serves as a fundamental stabilizer, providing long-term sustainability for pharmaceutical developers. Governments regard smallpox as a severe biological weapon threat, requiring maintained reserves of second-generation vaccines and antivirals irrespective of current infection levels. This security-focused approach results in multi-year contracts that protect companies from commercial volatility, as seen when SIGA Technologies announced in July 2024 that the U.S. Department of Health and Human Services exercised a $113 million procurement option for oral TPOXX. Furthermore, Emergent BioSolutions reported in July 2024 that it secured a $99.9 million contract modification to continue supplying the ACAM2000 vaccine to the U.S. Strategic National Stockpile, underscoring the sector's dependence on federal defense spending.

Market Challenge

The dependence on irregular government contracts acts as a major restraint on the global smallpox treatment market, generating a volatile revenue landscape that discourages steady private sector investment. In contrast to commercial pharmaceutical areas driven by consistent patient needs, this market relies heavily on biodefense stockpiling mandates and sporadic procurement cycles. Manufacturers must sustain costly, specialized production capabilities and regulatory readiness without the assurance of recurring sales, creating a boom-and-bust dynamic where income can disappear suddenly if threats are perceived to diminish or public health priorities change, thereby complicating long-term strategic planning.

This instability is worsened by the conditional nature of procurement, which frequently occurs only during active emergencies rather than through consistent preventative funding. This reactive model forces companies to bear the risks associated with capacity maintenance and inventory management. For example, UNICEF launched an emergency tender in 2024 to potentially acquire up to 12 million mpox vaccine doses through 2025, yet the acquisition was explicitly dependent on confirmed demand and available financing. This case illustrates how the reliance on unsecured public funding and the absence of a guaranteed commercial consumer base impede the market's capacity to sustain a stable growth trajectory.

Market Trends

Manufacturers and regulatory bodies are renewing their focus on extending drug labels to include special risk groups and pediatric populations, addressing a significant gap in historical biodefense strategies that previously excluded these demographics. This trend involves increasing regulatory actions and clinical trials specifically aimed at children to ensure broad protection against orthopoxviruses, pivoting toward the deployment of safer, third-generation vaccines that induce immunity in younger subjects without the severe side effects of earlier formulations. In a key development, the World Health Organization reported in November 2024 that it granted emergency approval for the LC16m8 vaccine for children over one year old and facilitated the donation of 3.05 million doses from Japan to the Democratic Republic of the Congo to safeguard this vulnerable group.

Biopharmaceutical firms are increasingly combining their research and development pipelines for mpox and smallpox, using active outbreaks to validate dual-indication therapeutics. By leveraging clinical data from mpox cases, developers can expedite regulatory approval pathways for broad-spectrum orthopoxvirus countermeasures that would otherwise be challenging to test due to the eradication of smallpox. This strategic consolidation optimizes R&D expenditure and ensures new platforms, such as mRNA technology, can quickly address emerging threats while fulfilling long-term government biodefense obligations, as demonstrated by Moderna's advancement of a Phase 1/2 clinical trial for its mRNA-1769 candidate against both viruses, reported by Pharmaceutical Technology in September 2024.

Key Market Players

  • Bavarian Nordic A/S
  • Chimerix, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Novartis AG
  • Johnson & Johnson
  • SIGA Technologies, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Bharat Biotech International Ltd

Report Scope

In this report, the Global Smallpox Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Smallpox Treatment Market, By Treatment Type

  • Antiviral Drugs
  • Vaccination
  • Supportive Care

Smallpox Treatment Market, By Product Type

  • Vaccines
  • Antiviral Drugs

Smallpox Treatment Market, By End user

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Smallpox Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Smallpox Treatment Market.

Available Customizations:

Global Smallpox Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Smallpox Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Antiviral Drugs, Vaccination, Supportive Care)
    • 5.2.2. By Product Type (Vaccines, Antiviral Drugs)
    • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Smallpox Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Product Type
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Smallpox Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Smallpox Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Smallpox Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By End user

7. Europe Smallpox Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Product Type
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Smallpox Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By End user
    • 7.3.2. France Smallpox Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Smallpox Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Smallpox Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Smallpox Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By End user

8. Asia Pacific Smallpox Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Product Type
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Smallpox Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By End user
    • 8.3.2. India Smallpox Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Smallpox Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Smallpox Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Smallpox Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By End user

9. Middle East & Africa Smallpox Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Product Type
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Smallpox Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Smallpox Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Smallpox Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By End user

10. South America Smallpox Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Product Type
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Smallpox Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Smallpox Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Smallpox Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Smallpox Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bavarian Nordic A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Chimerix, Inc.
  • 15.3. Pfizer Inc.
  • 15.4. Sanofi SA
  • 15.5. GlaxoSmithKline plc
  • 15.6. Novartis AG
  • 15.7. Johnson & Johnson
  • 15.8. SIGA Technologies, Inc.
  • 15.9. BioCryst Pharmaceuticals, Inc.
  • 15.10. Bharat Biotech International Ltd

16. Strategic Recommendations

17. About Us & Disclaimer